- Home
- AUST vs PLUR Comparison
AUST vs PLUR Comparison
Compare AUST & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | PLUR |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 28.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUST | PLUR |
|---|---|---|
| Price | $2.20 | $3.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.9M | 12.0K |
| Earning Date | 02-26-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,326,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 121.74 |
| 52 Week Low | $1.05 | $2.82 |
| 52 Week High | $3.92 | $7.13 |
Technical Indicators
Market Signals| Indicator | AUST | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 67.30 | 53.66 |
| Support Level | $1.71 | $3.00 |
| Resistance Level | $3.92 | $3.50 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 26.60 | 66.10 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.